BamSEC and AlphaSense Join Forces
Learn More

CTI BioPharma Corp

Formerly NASDAQ: CTIC
Search in Documents
Key Exhibits
External Links

Underwriting Agreements Filter

EX-1.2
from S-3 38 pages Open Market Sale Agreementsm
12/34/56
EX-1.1
from 8-K 36 pages 14,260,800 Shares of Common Stock 600 Shares of Series X1 Preferred Stock CTI BioPharma Corp. Underwriting Agreement March 31, 2021
12/34/56
EX-1.1
from 8-K 39 pages Open Market Sale Agreementsm
12/34/56
EX-1
from S-8 1 page Certificate of Amendment to the Certificate of Incorporation of CTI BioPharma Corp
12/34/56
EX-1
from 8-K 20 pages Amended and Restated 2017 Equity Incentive Plan CTI BioPharma Corp
12/34/56
EX-1
from 8-K 18 pages Registered Office
12/34/56
EX-1
from 8-K 1 page March 6, 2020 CTI BioPharma Corp. 3101 Western Avenue, Suite 800 Seattle, Washington 98191 Re: CTI BioPharma Corp. Registration Statement on Form S‑3 (File No. 333-221382) Ladies and Gentlemen
12/34/56
EX-1
from 8-K 36 pages Investment Agreement
12/34/56
EX-1
from 8-K 24 pages Corporate Presentation February 3rd, 2020 © Copyright 2020 CTI BioPharma Corp. All Rights Reserved
12/34/56
EX-1.1
from 8-K 39 pages Open Market Sale Agreementsm
12/34/56
EX-1
from 8-K 25 pages Corporate Presentation January 7, 2019 © Copyright 2019 CTI BioPharma Corp. All Rights Reserved
12/34/56
EX-1
from 8-K 2 pages CTI BioPharma Announces Completion of Enrollment in the Phase 2 Pac203 Study of Pacritinib - Optimal Dose Determination From the Pac203 Study Expected in Mid-2019 With Topline Data Expected in the Third Quarter of 2019
12/34/56
EX-1
from 8-K 2 pages CTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development From the European Medicines Agency - European Regulatory Opinion on Marketing Authorization Application (Maa) for Pacritinib Now Expected in the First Quarter of 2019
12/34/56
EX-1.1
from 8-K 35 pages CTI BioPharma Corp. $50,000,000 Common Stock Sales Agreement
12/34/56
EX-1
from 8-K 14 pages Underwriting agreement
12/34/56
EX-1
from 8-K 27 pages Corporate Presentation August 15, 2018 © Copyright 2018 CTI BioPharma Corp. All Rights Reserved
12/34/56
EX-1
from 8-K 2 pages Underwriting agreement
12/34/56
EX-1.1
from 8-K 51 pages 20,000,000 Shares CTI BioPharma Corp. Common Stock Underwriting Agreement
12/34/56
EX-1.1
from 8-K ~50 pages 22,500 Shares CTI BioPharma Corp. Series N-3 Preferred Stock Underwriting Agreement
12/34/56
EX-1.1
from 8-K 30 pages 55,000 Shares CTI BioPharma Corp. Series N-2 Preferred Stock Underwriting Agreement
12/34/56